HIGH GRADE GLIOMA OF CENTRAL NERVOUS SYSTEM: SINGLE CENTER TREATMENT EXPERIENCE
Objective: To evaluate characteristics and treatment responses of patients with high grade gliomas (HGG) in our center. Medical files of patients with malignant CNS tumors between 1987-2020 were analyzed retrospectively. There were 44 patients with HGG. Case report: Diagnosis of patients as follows:...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-11-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137921012402 |
| _version_ | 1818990072826953728 |
|---|---|
| author | Nur OLGUN Deniz KIZMAZOGLU Dilek INCE Emre CECEN Şefika AKYOL Ayşe ONAL Batuhan OZDOGAR Ceren KIZMAZOGLU Ayşe DEMIRAL Rıza CETINGOZ Handan UCAR Erdener OZER |
| author_facet | Nur OLGUN Deniz KIZMAZOGLU Dilek INCE Emre CECEN Şefika AKYOL Ayşe ONAL Batuhan OZDOGAR Ceren KIZMAZOGLU Ayşe DEMIRAL Rıza CETINGOZ Handan UCAR Erdener OZER |
| author_sort | Nur OLGUN |
| collection | DOAJ |
| description | Objective: To evaluate characteristics and treatment responses of patients with high grade gliomas (HGG) in our center. Medical files of patients with malignant CNS tumors between 1987-2020 were analyzed retrospectively. There were 44 patients with HGG. Case report: Diagnosis of patients as follows: 21 pons glioma, 2 anaplastic astrocytoma, 11 anaplastic ependimoma, 7 glioblastoma multiforme, 1 glioblastoma, 2 gliomatosis cerebri. The median age at diagnosis was 6,5 yrs (7 – 17 yrs), M/F:25/19. Age distribution: <5 yrs 12 patients, 5-10 yrs 18 patients, 10-18 yrs 14 patients. The most frequent complaints for pons gliomas: cranial nerve paralysis (52%), visual impairment (48%), headache (38%), power loss (43%) and speech disorder (30%). Methodology: Surgery was performed to extrinsic component of mass in 3 patients of pons gliomas.For other HGG: 7 subtotal resection and 16 gross total resection had performed.7 patients died before RT. And other 37 patients received radiotherapy. RT total doses varied between 50-60 Gy.7 patients were not received chemotherapy, 3 of them died before chemo, and others received only RT. For other HGGs, platin based regimens used for the first line treatment. Temozolamide, bevacizumab, irinotecan as the other options. Results: Median progression free survival time was 6 mos (2weeks-25 mos) for pons gliomas, for other gliomas median progression free survival time was 14 mos(0 -74 mos).For pons gliomas: Event free survival rate for 6 mos was 75%, for one year 17%;one year, 18 mos, and two years overall survival rates were 84%,52% and 10%respectively.For other HGGs: Event free survival rate for one year and two years were 57% and 17% respectively. One year and two years overall survival rates were 73% and 36% respectively. Conclusion: High grade glioma is a group of tumors in which still the helplessness experienced in treatment. Despite radiotherapy and chemotherapy, prognosis is very poor. The progression free and overall survival rates of patients were similar to literature. With new developments in molecular pathology, as the use of molecular target therapies, the progression free survival rates newly will improve. |
| first_indexed | 2024-12-20T19:48:34Z |
| format | Article |
| id | doaj.art-6223bbd81eb14c43a6753a4d27825dd3 |
| institution | Directory Open Access Journal |
| issn | 2531-1379 |
| language | English |
| last_indexed | 2024-12-20T19:48:34Z |
| publishDate | 2021-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hematology, Transfusion and Cell Therapy |
| spelling | doaj.art-6223bbd81eb14c43a6753a4d27825dd32022-12-21T19:28:21ZengElsevierHematology, Transfusion and Cell Therapy2531-13792021-11-0143S63S64HIGH GRADE GLIOMA OF CENTRAL NERVOUS SYSTEM: SINGLE CENTER TREATMENT EXPERIENCENur OLGUN0Deniz KIZMAZOGLU1Dilek INCE2Emre CECEN3Şefika AKYOL4Ayşe ONAL5Batuhan OZDOGAR6Ceren KIZMAZOGLU7Ayşe DEMIRAL8Rıza CETINGOZ9Handan UCAR10Erdener OZER11Dokuz Eylul University Institute of Oncology, Pediatric OncologyDokuz Eylul University Institute of Oncology, Pediatric OncologyDokuz Eylul University Institute of Oncology, Pediatric OncologyDokuz Eylul University Institute of Oncology, Pediatric OncologyDokuz Eylul University Institute of Oncology, Pediatric OncologyDokuz Eylul University Institute of Oncology, Pediatric OncologyDokuz Eylül University Faculty of Medicine, Department of PediatricsDokuz Eylül University Faculty of Medicine, Department of NeurosurgeryDokuz Eylül University Faculty of Medicine, Department of Radiation OncologyDokuz Eylül University Faculty of Medicine, Department of Radiation OncologyDokuz Eylul University Faculty of Medicine, Department of RadiodiagnosticDokuz Eylül University Faculty of Medicine, Department of PathologyObjective: To evaluate characteristics and treatment responses of patients with high grade gliomas (HGG) in our center. Medical files of patients with malignant CNS tumors between 1987-2020 were analyzed retrospectively. There were 44 patients with HGG. Case report: Diagnosis of patients as follows: 21 pons glioma, 2 anaplastic astrocytoma, 11 anaplastic ependimoma, 7 glioblastoma multiforme, 1 glioblastoma, 2 gliomatosis cerebri. The median age at diagnosis was 6,5 yrs (7 – 17 yrs), M/F:25/19. Age distribution: <5 yrs 12 patients, 5-10 yrs 18 patients, 10-18 yrs 14 patients. The most frequent complaints for pons gliomas: cranial nerve paralysis (52%), visual impairment (48%), headache (38%), power loss (43%) and speech disorder (30%). Methodology: Surgery was performed to extrinsic component of mass in 3 patients of pons gliomas.For other HGG: 7 subtotal resection and 16 gross total resection had performed.7 patients died before RT. And other 37 patients received radiotherapy. RT total doses varied between 50-60 Gy.7 patients were not received chemotherapy, 3 of them died before chemo, and others received only RT. For other HGGs, platin based regimens used for the first line treatment. Temozolamide, bevacizumab, irinotecan as the other options. Results: Median progression free survival time was 6 mos (2weeks-25 mos) for pons gliomas, for other gliomas median progression free survival time was 14 mos(0 -74 mos).For pons gliomas: Event free survival rate for 6 mos was 75%, for one year 17%;one year, 18 mos, and two years overall survival rates were 84%,52% and 10%respectively.For other HGGs: Event free survival rate for one year and two years were 57% and 17% respectively. One year and two years overall survival rates were 73% and 36% respectively. Conclusion: High grade glioma is a group of tumors in which still the helplessness experienced in treatment. Despite radiotherapy and chemotherapy, prognosis is very poor. The progression free and overall survival rates of patients were similar to literature. With new developments in molecular pathology, as the use of molecular target therapies, the progression free survival rates newly will improve.http://www.sciencedirect.com/science/article/pii/S2531137921012402 |
| spellingShingle | Nur OLGUN Deniz KIZMAZOGLU Dilek INCE Emre CECEN Şefika AKYOL Ayşe ONAL Batuhan OZDOGAR Ceren KIZMAZOGLU Ayşe DEMIRAL Rıza CETINGOZ Handan UCAR Erdener OZER HIGH GRADE GLIOMA OF CENTRAL NERVOUS SYSTEM: SINGLE CENTER TREATMENT EXPERIENCE Hematology, Transfusion and Cell Therapy |
| title | HIGH GRADE GLIOMA OF CENTRAL NERVOUS SYSTEM: SINGLE CENTER TREATMENT EXPERIENCE |
| title_full | HIGH GRADE GLIOMA OF CENTRAL NERVOUS SYSTEM: SINGLE CENTER TREATMENT EXPERIENCE |
| title_fullStr | HIGH GRADE GLIOMA OF CENTRAL NERVOUS SYSTEM: SINGLE CENTER TREATMENT EXPERIENCE |
| title_full_unstemmed | HIGH GRADE GLIOMA OF CENTRAL NERVOUS SYSTEM: SINGLE CENTER TREATMENT EXPERIENCE |
| title_short | HIGH GRADE GLIOMA OF CENTRAL NERVOUS SYSTEM: SINGLE CENTER TREATMENT EXPERIENCE |
| title_sort | high grade glioma of central nervous system single center treatment experience |
| url | http://www.sciencedirect.com/science/article/pii/S2531137921012402 |
| work_keys_str_mv | AT nurolgun highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT denizkizmazoglu highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT dilekince highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT emrececen highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT sefikaakyol highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT ayseonal highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT batuhanozdogar highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT cerenkizmazoglu highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT aysedemiral highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT rızacetingoz highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT handanucar highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT erdenerozer highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience |